Prosecutors will oppose a bid by ANZ, Citigroup, and Deutsche Bank to cross-examine witnesses at the upcoming committal hearing of the criminal cartel case over ANZ’s botched $2.5 billion institutional share placement.
German-based cladding manufacturer 3A Composites has foreshadowed potential cross claims against third party engineers and certifiers in one of two class actions brought over allegedly dangerous combustible cladding used in countless buildings across Australia.
APRA has been accused of harbouring an “unhinged hatred” for former IOOF managing director Chris Kelaher by his counsel, who was objecting to internal APRA documents he claims were disparaging of the wealth management company and its executives.
The prudential regulator has opened the first day of its case against IOOF directors and entities by claiming the wealth manager’s liability is “plain as a pike staff”, as IOOF contends the regulator’s case is “artificial and theoretical” and “overly simplistic”.
The Australian Competition and Consumer Commission has lost its case alleging Kimberly-Clark made misleading representations about its flushable wipes, with a judge finding the consumer regulator failed to provide sufficient evidence to show the wipes caused harm to sewage systems.
The funder backing the IAG add-on insurance class action has agreed to a fixed 25 per cent commission, after the plaintiff copped criticism from a judge for the largely redacted funding agreement which called for lower rates if the case settled by a certain date.
The judge overseeing several class actions over the alleged use of toxic foam at government military bases has appointed a special counsel to hear the Commonwealth’s claims that it should be exempt for producing certain documents due to public interest immunity and legal professional privilege.
The High Court of Australia has resolved a nearly 40-year old question of whether employees of a failed company established as trustee of a trading trust have priority over ordinary unsecured creditors.
Israeli drug giant Teva and German drug maker Boehringer Ingelheim have settled their dispute over a patented capsule used to deliver the medicine in Boehringer’s top-selling inhaler Spiriva.
While no means a flood, the class actions filed in response to the shocking evidence of misbehaviour at last year’s banking royal commission have been steadily flowing and show no signs of drying up. Here, we give you the round-up of cases launched so far, the latest developments in each, and what’s coming down the pipeline.